{"title":"子宫内膜癌中的雌激素和孕激素受体:我们今天在哪里?","authors":"Swasti","doi":"10.4172/2161-0932.1000E127","DOIUrl":null,"url":null,"abstract":"Immunohistochemistry of estrogen receptor (ER) and progesterone receptor (PR) is not routinely adopted by clinicians for the management of endometrial cancers. However, they may have significant importance in determining tumor behaviour and selection of an appropriate treatment protocol. An insight into the role of ER and PR in endometrial cancers is needed for optimizing outcome. The mechanism of action of these receptors in endometrial carcinoma needs to be clearly understood.","PeriodicalId":22164,"journal":{"name":"Surgery, gynecology & obstetrics","volume":"15 1","pages":"1-2"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Estrogen and Progesterone Receptors in Endometrial Cancer: Where Are We Today?\",\"authors\":\"Swasti\",\"doi\":\"10.4172/2161-0932.1000E127\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Immunohistochemistry of estrogen receptor (ER) and progesterone receptor (PR) is not routinely adopted by clinicians for the management of endometrial cancers. However, they may have significant importance in determining tumor behaviour and selection of an appropriate treatment protocol. An insight into the role of ER and PR in endometrial cancers is needed for optimizing outcome. The mechanism of action of these receptors in endometrial carcinoma needs to be clearly understood.\",\"PeriodicalId\":22164,\"journal\":{\"name\":\"Surgery, gynecology & obstetrics\",\"volume\":\"15 1\",\"pages\":\"1-2\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Surgery, gynecology & obstetrics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2161-0932.1000E127\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgery, gynecology & obstetrics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2161-0932.1000E127","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Estrogen and Progesterone Receptors in Endometrial Cancer: Where Are We Today?
Immunohistochemistry of estrogen receptor (ER) and progesterone receptor (PR) is not routinely adopted by clinicians for the management of endometrial cancers. However, they may have significant importance in determining tumor behaviour and selection of an appropriate treatment protocol. An insight into the role of ER and PR in endometrial cancers is needed for optimizing outcome. The mechanism of action of these receptors in endometrial carcinoma needs to be clearly understood.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
